GMAB
- Genmab A/S
()
Overview
Company Summary
Genmab A/S (GMAB) is a global biotechnology company focused on the discovery, development, and commercialization of innovative antibody-based therapies for the treatment of cancer and other diseases.
The company specializes in creating monoclonal antibodies, which are proteins designed to target specific molecules in the body, such as cancer cells or the immune system, to help fight diseases. These antibodies are generated using Genmab's proprietary technology platforms, including their transgenic mouse technology and antibody engineering expertise.
Genmab works in close collaboration with pharmaceutical partners and academic institutions to develop their pipeline of product candidates. They conduct rigorous research and development, including preclinical and clinical trials, to test the safety and effectiveness of their therapies.
One of Genmab's most notable achievements is the development of daratumumab (marketed as Darzalex�) in collaboration with Janssen Biotech. This antibody has been approved for the treatment of multiple myeloma, a form of blood cancer, and has revolutionized the treatment of this disease.
In addition to daratumumab, Genmab has a robust pipeline with several other investigational antibody candidates in various stages of development. These candidates target a range of diseases, including hematological malignancies, solid tumors, and autoimmune disorders.
Overall, Genmab A/S is dedicated to pushing the boundaries of scientific research and innovation in the field of antibody-based therapies, with the ultimate goal of improving patients' lives and transforming the way diseases are treated.